Dysthyroid optic neuropathy: update on pathogenesis, diagnosis, and management by Blandford, Alexander D. et al.
Dysthyroid optic neuropathy: update on pathogenesis, 
diagnosis, and management
Alexander D. Blandford, MD1, Dalia Zhang2, Rao V. Chundury, MD, MBA3, and Julian D. 
Perry, MD1
1Cole Eye Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
2Case Western Reserve University School of Medicine, 2109 Adelbert Road, Cleveland, OH 
44106
3Eugene and Marilyn Glick Eye Institute, Indiana University, 1160 W Michigan St, Indianapolis, IN 
46202
Abstract
Introduction—Dysthyroid optic neuropathy (DON) is a severe manifestation of thyroid eye 
disease (TED) that can result in permanent vision loss. Management is complex, multidisciplinary, 
and involves medical and/or surgical therapies. This review describes current concepts in the 
epidemiology, pathophysiology, diagnosis, and treatment of DON.
Areas covered—An extensive review of the literature was performed to detail current concepts 
on the diagnosis and management of DON. This includes utilization of various medical and 
surgical modalities for disease management.
Expert commentary—DON can result in permanent blindness and often requires the use of 
corticosteroids and surgical decompression. We favor the use of intravenous corticosteroids and a 
transcaruncular approach when surgical decompression is indicated. The use of orbital radiation 
for DON is often reserved for patients that are poor surgical candidates and/or patients with 
refractory disease.
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1. Introduction
Thyroid eye disease (TED) represents the most common extraocular manifestation of 
Graves’ disease (GD). While the pathophysiology behind Graves’ hyperthyroidism is fairly 
well understood, that of Graves’ orbitopathy is less so. Approximately 50% of patients with 
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GD will suffer from TED before, during, or after the development of hyperthyroidism. 
While about 60 percent only experience mild discomfort related to eyelid retraction, some 
35% will suffer from diplopia interfering with daily life activities or disfiguring proptosis, 
and finally 3–7 % develop vision threatening complications such as dysthyroid optic 
neuropathy (DON)[1]. This review provides a consolidated overview of our current 
understanding of DON.
2. Overview and Epidemiology
The overall prevalence of GD is 13.9 per 100,000 in the United States, with no significant 
ethnic predisposition[2]. Approximately 25–50% of these patients will display clinically 
apparent ophthalmopathy, though imaging reveals subclinical features in the majority[2,3]. 
The gender distribution of patients with TED shows a 5:1 predominance of females over 
males, yet patients with severe eye disease are more likely to be male and over age 60 
years[1,2,4,5].
The natural history of TED is characterized by an active inflammatory phase lasting about 
1–3 years and followed by an inactive fibrotic phase [6]. About 1% of patients experience 
recurrence of active disease, sometimes years following remission. While the majority of 
patients who develop TED exhibit mild-to-moderate symptoms that require only supportive 
treatments, about 3–7% experience severe inflammation resulting in sight-threatening 
ophthalmopathy from exposure keratopathy or DON[2]. (FIGURE 1)
3. Risk Factors
Several genes related to immune modulation, thyroid hormone metabolism and other 
mechanisms have been implicated in the pathogenesis of TED, however none has been 
found to be necessary, sufficient, or specific to the development of TED and/or DON[3]. 
Numerous other risk factors are associated with TED including age, gender, genetics, 
smoking, thyroid dysfunction, as well as treatments for hyperthyroidism. Discordant 
identical twin studies suggest that both genetic and environmental factors[7]. Some of these 
risk factors may also be associated with the development of DON.
The prevalence of smokers in patients with TED is markedly high relative to all other 
thyroid disorders[8]. Tobacco use is associated with a 7–8× increased risk for developing 
TED, increased disease severity, and a dampened response to treatment[9,10]. Smoking may 
represent a risk factor for DON as well, although the evidence is not as overwhelming. A 
recent review of 604 patients with Grave’s orbitopathy found an odds ratio (OR) of 1.5 for 
current smokers developing DON, but this was not statistically significant[11]. Wiersinga et 
al identified male sex, older age, and heavy smoking as the biggest risk factors for 
developing DON, however no detailed statistics were provided[12]. Another retrospective 
study found smoking to be the strongest predictive factor in the development of both severe 
TED (OR = 6.57) and DON (OR = 10.00)[13].
Diabetes mellitus (DM) has also been cited as a risk factor for TED. There exists a complex 
interplay between glycemic control and thyroid function. While the prevalence of diabetic 
patients with TED is similar to the normal population (0.22 – 0.26%), the prevalence of 
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patients with insulin-dependent diabetes mellitus (IDDM) is significantly higher (1.7%), and 
among these patients, the disease course is generally more severe and refractory [14]. The 
vasculopathy associated with DM leads to marginal oxygenation of the optic nerve, leaving 
it more susceptible to damage due to EOM expansion and optic nerve compression. In one 
study, while only 3.1% of patients with TED had diabetes and 3.9% developed DON, 33.3% 
of patients with diabetes eventually developed DON. Medical and/or surgical treatment may 
be less effective in improving visual outcome for patients with diabetes[15].
Thyroid dysfunction is closely related to the development and severity of TED. 
Dysthyroidism has long been observed to contribute to the development and progression of 
TED; potential risk cofactors include hypothyroidism as well as the severity, duration, and 
recent onset of hyperthyroidism. Establishment and maintenance of euthyroidism is 
essential[16]. The specific treatment of thyroid dysfunction may impact the course of 
TED[16]. Radioiodine (RAI) therapy may increase the risk of TED progression by 15–39% 
over anti-thyroid medications or thyroidectomy[3]. In the same way, RAI may increase the 
risk of developing DON, although no meaningful data exist to validate this extrapolation.
Age and gender also appear to influence the severity of TED, including the development of 
DON. Increased age correlates with greater severity of thyroid eye disease and age may 
represent one of the biggest risk factors for DON[2,5]. Patients with DON are significantly 
older than those with TED alone, with an average age of 61 years[4]. In another large 
retrospective study, 8.6% of patients with TED developed DON, and patients with DON 
were older (54 years versus 46 years)) compared to those without DON[1]. Several other 
studies also show a strong correlation between age and DON [17,18]. For every decade 
increase in age of onset of TED, the odds of developing DON may increase by 58%[11]. 
Age may also affect the response to DON treatment with younger age predicting a better 
outcome (p=0.049)[19]. Male gender also shows a strong correlation with the development 
of DON, especially with advancing age[1,4,5,17].
4. Pathophysiology
The pathogenesis of DON has been described as having mechanical, vascular, and 
inflammatory components. The most widely accepted mechanism is secondary to an apex or 
compartment syndrome from orbital fibroblast deposition of hyaluronic acid (HA) leading to 
extraocular muscle (EOM) enlargement, enlargement of orbital fat, and overall increased 
vascular congestion[1,20–25].
As the EOMs converge at the orbital apex, their common insertions form the annulus of 
Zinn. Here, the medial rectus is most proximal to the optic nerve and compression from 
EOM swelling can cause optic nerve ischemia or inhibit axonal flow. The medial rectus 
volume, which can be approximated by medial rectus axial diameter, seems to be the 
strongest predictor of DON[26]. Orbital computed tomography (CT) studies demonstrate 
significant optic nerve crowding at the orbital apex in the vast majority of patients with 
DON, and may also demonstrate intracranial fat prolapse or an increased superior 
ophthalmic vein diameter[1,23,27,28]. Also implicating direct optic nerve compression in 
DON is that retrobulbar pressure markedly decreases after decompression surgery[29].
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Orbital fibroblasts represent the main effector cells in TED; in addition to producing HA to 
cause congestion and compression, fibroblasts may differentiate and proliferate[11]. The 
TSH receptor serves as the autoimmune target in TED and antibody levels correlate with 
disease activity and severity. Orbital fibroblasts in TED, as compared to normal individuals, 
express higher levels of TSH receptor, suggesting its potential role as an autoantigen[30]. 
Insulin-like growth factor-1 receptor (IGF-1R) appears to activate orbital fibroblasts to cause 
cell proliferation, adipogenesis, and HA synthesis[30]. A subset of fibroblasts may arise 
from fibrocytes, which are CD34+ mesenchymal cells derived from bone marrow. These 
circulate as mononuclear cells capable of infiltrating tissue to participate in inflammation, 
healing, and fibrosis. This leads to fibrotic, less compliant muscles in the apex, which may 
contribute to the development of DON[20]. (FIGURE 2)
In addition to apex compression and inflammation, changes in orbital vasculature may relate 
to DON. Doppler sonography shows the superior ophthalmic vein as the most susceptible to 
changes, exhibiting decreased flow in the active stage and reversed or absent flow in the 
setting of severe orbitopathy[31]. These vascular changes may contribute to DON. Rarely, 
short optic nerve or stretch of the optic nerve may cause DON in the absence of EOM 
involvement[32]. The mechanism by which this occurs may involve the optic nerve 
vasculature to produce ischemia.
5. Clinical presentation and diagnosis
Multiple objective measures grade the physical signs, symptoms, and severity of TED, 
including NO SPECS, CAS, VISA, and EUGOGO (Table 1 and 2) however, no single 
protocol completely characterizes DON [33–36]. Patients may be classified as Type I or 
Type II, with predominantly fat or EOM enlargement, respectively [37]. Type II orbitopathy 
may more commonly produce DON, as patients with a muscle index <50% rarely develop 
DON[21,23,28]. Further, retrobulbar fat volume compares similarly in TED patients with or 
without DON. Alternatively, Type I and Type II classifications may simply represent 
extremes on the sprectrum of disease presentation; results from a large tertiary referral 
center found that the majority of patients presenting with TED demonstrated predominantly 
an increase of their orbital muscle volume[38].
Most clinicians utilize a combination of clinical and radiological findings to diagnose DON. 
Tissue enlargement in patients with DON often results in congestion at the orbital apex 
rather than severe proptosis, and patients may not demonstrate external signs of overt orbital 
inflammation[25]. The visual acuity often lags behind other symptoms and signs of DON. 
Color vision, pupillary exam, contrast sensitivity, and automated visual field perimetry help 
characterize optic nerve function for the diagnosis and management of DON, and DON may 
result in some characteristic changes in these tests. (FIGURE 3)
Visual acuity decline in TED often occurs from etiologies other than DON, including tear 
film abnormalities, poor blink, exposure, and resultant corneal irregularities[23]. While 
decreased acuity is nonspecific, it is decreased more in eyes with DON compared to those 
with TED alone. In one study, only 53% of patients with DON had visual acuity of 20/40 or 
better, compared to 97% of patients having TED without DON[1].
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An afferent pupillary defect in the setting of TED is highly specific for DON[1]. However, it 
may be absent in bilateral DON, or it may occur for reasons other than DON. Color vision 
changes represent an early sign of optic nerve compression. Contrast sensitivity may 
diminish in TED patients who do not show other signs of DON, indicating this test may 
detect subclinical optic nerve damage early in the disease process[39].
Visual field testing accurately detects DON[14]. Nearly all eyes with DON develop a central 
or paracentral scotoma, and many develop other peripheral breakout patterns as well, 
including inferior arcuate defects, inferior altitudinal, increased blind spot/nerve bundle 
defect generalized field constriction, and inferolateral defects[1,4]. Visual Evoked Potential 
(VEP) may also help detect and follow DON, and it may be more sensitive than kinetic 
perimetry[1,40,41].
Orbital imaging techniques, particularly CT imaging, help to diagnosis and follow DON. 
Imaging gains particular importance in patients with bilateral disease as an afferent pupillary 
defect and color testing are less useful in this situation[21]. It is also important when other 
diagnostic tests do not clearly point to DON, as almost all patients with DON demonstrate 
CT imaging findings.
In addition to apical crowding, the overwhelming majority of CT imaging studies in cases of 
DON demonstrate moderate to severe muscle enlargement[1] (FIGURE 4A/4B). The muscle 
index represents a way to approximate the relative EOM volume within the orbit, and is 
significantly greater in orbits with DON than in orbits with TED alone[21]. The muscle 
index is calculated viewing a posterior coronal image of the orbit halfway between the 
orbital apex and the posterior globe. A horizontal line is drawn to transect the optic nerve, 
medial, and lateral rectus muscles. A vertical line is drawn to transect the optic nerve, 
superior, and inferior rectus muscles. The horizontal muscle index is calculated by the 
percentage of the orbital width that is occupied by the medial and lateral rectus muscles. The 
vertical muscle index is calculated by the percentage of orbital height that is occupied by the 
superior and inferior rectus muscles. A muscle index of greater than 70% is seen in about 
2/3 of cases of DON, and DON almost never occurs in the setting of a muscle index < 
50%[21,23,28].
Orbital fat prolapse through the superior orbital fissure may predict DON, with up to 94% 
sensitivity, 91% specificity, a positive predict value of 69%, and a negative predictive value 
of 98%, however, a recent study found this feature in a lower percentage of cases of 
DON[22,23,47]. Enlargement of the superior ophthalmic vein may also predict DON[28]. 
An anteriorly displaced or enlarged lacrimal gland may also be seen in the setting of TED 
and possibly DON[48–50].
Magnetic resonance imaging (MRI) may reveal findings similar to CT imaging, but allows 
for superior soft tissue imaging[51–54]. T2-weighted and fat suppressed images using TIRM 
(Turbo-Inversion-Recovery-Magnitude) and STIR (Short-Tau Inversion Recovery) 
sequences enable detection of extraocular muscle/orbital fat interstitial edema and therefore 
disease activity. This makes MRI ideal for distinguishing active inflammatory TED from 
fibrotic end stage disease and is critical to the type and timing of treatment[51,55,56]. MRI 
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changes of the optic nerve may correlate with clinical activity scores, suggesting that future 
MR imaging studies of the optic nerve itself may help detect DON[51,55,57–59]. Although 
MRI is superior at imaging soft tissue, CT is better at evaluating bony orbital anatomy, 
which is critical for surgical planning.
6. Treatment overview
As the majority of patients with TED develop only mild-moderate symptoms that improve 
spontaneously, supportive and conservative treatment generally suffices[60]. For patients 
with moderate-severe and active TED, therapy may reduce disease duration and severity. 
First line treatment generally consists of oral or intravenous (IV) glucocorticoids, and 
possibly orbital radiotherapy (ORT). Management of hyperthyroidism should be considered 
carefully, as dysthyroidism may precipitate disease progression and the treatment modality 
may affect the course of the disease, though this still remains unclear. Other 
immunosuppressive and biologic agents, such as methotrexate, rapamycin, adalimumab, and 
rituximab, have been investigated but are generally second line therapies. Rehabilitative 
surgery is best performed after cessation of active disease, but may be required earlier for 
cases of DON refractory to medical treatment.
There exists no consensus regarding the best treatment strategy for TED or DON. American 
Society of Ophthalmic and Reconstructive Surgery (ASOPRS) members chose both oral 
(43% of members) and IV (49% of members) steroids as first line treatments for severe 
TED. In contrast, European and Latin American physicians favor the use of IV over oral 
steroids as first line therapy[61]. ASOPRS members also use orbital decompression (83%), 
ORT (70%), biologic agents (33%), and intraorbital steroid injections (28%). Sight-
threatening TED may involve a combination of these treatments.
7. Corticosteroids
Corticosteroids are the most widely used medical treatment for DON. Locally administered 
peribulbar steroids, such as triamcinolone acetonide may improve CAS with fewer side 
effects compared to oral glucocorticoids, but their effect on DON is less clear[62].
Pulsed IV glucocorticoids (iv-GC) treat TED more effectively than oral steroids, with fewer 
adverse effects [16]. However, iv-GC may rarely produce severe complications, including 
fatal acute liver failure, as well as cardiovascular and cerebrovascular events. The majority 
of severe complications are associated with doses exceeding 8 grams and daily or alternate 
day intravenous methylprednisolone (iv-MP)[63,64]. A recent EUGOGO consensus 
statement advocates iv-GC as a first line treatment for moderate-severe TED[16]. A 
generally accepted dosing regimen for these patients is a once-per-week dose of 500 
milligrams iv-MP per week for 6 weeks, followed by 250 milligrams per week for another 6 
weeks[65]. Cumulative dose should remain under approximately 6–8g, and patients should 
be continuously monitored during treatment.
DON may necessitate more aggressive measures, such as 500–1,000 milligrams iv-MP daily 
for 3 consecutive days, and repeated if necessary after 1 week[64,66]. Regimens such as this 
may lead to complete visual recovery in approximately 43% of cases. Other iv-MP regimens 
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show similarly successful outcomes[67]. Some milder cases can be managed with oral 
steroids and careful monitoring. Because systemic glucocorticoids can effectively treat 
DON, they should be considered as a first line treatment in most cases.
8. Radiation Therapy
Many clinicians use ORT to treat moderate-to-severe TED. The most common dosing 
regimen calls for a cumulative dose of 20 Gy per eye, fractionated into ten doses over 10 
days[68]. This regimen has proven very safe, and side effects are typically mild (periorbital 
edema, hair loss at entry ports, and conjunctival injection) and regress after treatment[69]. 
Severe side effects such as radiation retinopathy, optic neuropathy, and scleral necrosis are 
rare, and typically in the setting of prior chemotherapy treatment, diabetes mellitus, or 
systemic hypertension. Absolute contraindications for radiation therapy include severe 
hypertension and diabetic retinopathy, while diabetes mellitus without retinopathy is 
considered a relative contraindication. ORT should be avoided in patients under age 35 
years[35,70]. (FIGURE 5) While existing data do not point to any clear and significant effect 
of ORT on the duration or severity of TED its role in treatment of DON are not well 
studied[71]. ORT does seem to play a preventative role in the development of DON, so it 
may also play a role in its treatment[72,73]. We typically use ORT in patients refractory to 
iv-MP who refuse surgery or who are poor surgical candidates.
9. Alternative Immunosuppressive Agents
A variety of steroid-sparing agents for TED and DON have been proposed and studied. 
Insights into new molecular pathways have exposed more specific targets for therapy. As 
Th-1 and macrophage type cytokines are implicated in the early stages of TED pathogenesis, 
agents targeting receptors for IL-1, IL-6, and TNF may be effective in treatment. These 
include anakinra, tocilizumab, lerdelimumab, infliximab, adalimumab, and etanercept[24]. 
Both TSHR and IGF-1R are potential targets for small molecule agents and monoclonal 
antibodies, such as M22 and teprotumumab[74,75]. Other options include modulation of co-
stimulatory pathways and inhibition of T-cell migration and response through blockade of 
CXCR3 signaling with agents such as peroxisome proliferator-activated receptor (PPAR) γ 
or α agonists, and CXCR3 antagonists[76].
Publications regarding the use of these agents for treatment of DON consist mostly of case 
reports, and small case series. Rapamycin was reported to improve symptoms, visual acuity, 
color plate testing, and visual fields in a case of DON refractory to steroids and maximal 
surgical decompression[77]. Adalimumab, an anti-TNF-α monoclonal antibody, was found 
in one retrospective study to significantly improve inflammation in active TED, but only in 
patients with a high inflammatory index at baseline[78]. Tocilizumab, an anti-IL-6 
monoclonal antibody, showed promising results in treatment of patients with corticosteroid-
resistant TED in a prospective interventional study[79]. Methotrexate improves CAS but 
may not completely treat DON[80]. Teprotumumab, an anti-IGF-1R monoclonal antibody, is 
currently under investigation in a clinical trial[81].
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Rituximab, an anti-CD20 monoclonal antibody, may be of some benefit in treating TED and 
DON[82–84]. This agent may improve both visual acuity and CAS in cases of DON 
refractory to steroids and surgical decompression[83]. However, in patients with moderate-
severe TED it may not significantly improve CAS as compared to placebo and may cause 
adverse events[85].
While further studies of rituximab and alternative immunosuppressive agents for DON seem 
warranted, newer agents in the future may prove more useful. When medical management of 
DON fails, efforts are directed at surgical decompression.
10. Surgical Decompression
Surgery for DON should decrease orbital soft tissue volume and/or expand its bony volume 
to decompress the optic nerve at the orbital apex. (FIGURE 6) Fat can be removed from any 
location within the orbit and the bony expansion can occur along any orbital wall. The 
inferomedial wall extends deeper into the orbital apex and generally represents the first-line 
approach to decompress the apex, although deep lateral wall bone removal and/or fat-only 
removal may also decompress the orbital apex. Several approaches to the medial wall have 
been described, including the transantral, transcutaneous, endonasal, and transcaruncular 
approaches.
11. Transantral
The transantral approach allows for removal of the inferior and medial orbital walls through 
a mucosal incision within the buccal sulcus, and removal of the anterior face of the maxilla. 
The technique can successfully treat DON, with improvement in visual acuity and visual 
field defects in approximately 91% of patients[86]. However, approximately 2/3 of patients 
may develop new-onset diplopia after surgery. Other complications include lower eyelid 
entropion (9%), alveolar branch trigeminal nerve hypoesthesia (5%), and CSF leak (3.5%)
[86].
12. Transcutaneous
A lower eyelid subciliary incision, either with or without a swinging eyelid approach, yields 
excellent exposure of the inferomedial orbit for treatment of DON[87,88]. The swinging 
eyelid approach allows for greater visualization of the inferolateral orbital fat and lateral 
wall[87].
Although the Lynch approach is almost obsolete, a smaller incision (1.5–2cm) 
transcutaneous medial approach yields adequate exposure and may result in less medial 
canthal webbing, telecanthus, iatrogenic diplopia, and damage to the lacrimal outflow 
system.[90,91].
13. Orbital fat decompression
Orbital fat can be removed during bony decompression or independently for treatment of 
DON. Transpalpebral extraconal and/or intraconal fat removal without bony decompression 
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(but with iv-GC and/or ORT) successfully treated DON in 69 patients, though the specific 
outcomes regarding patients with DON were not reported[92]. In patients with DON having 
only modest EOM enlargement and more fat compartment enlargement, fat decompression 
alone may reverse DON in all cases with minimal complications[93].
14. Endoscopic transnasal
The inferomedial orbit may also be decompressed via a transnasal endoscopic approach. 
Described in 1990 by Kennedy et al, the endonasal approach effectively treats DON, but 
may induce new diplopia in 60–80% of cases[94–96]. This may be due to the difficulty in 
maintaining an inferomedial bony strut via the endoscopic approach[95,97]. More recent 
attempts at selective posterior endoscopic decompression for DON may result in less post-
operative diplopia[95]. Fat can also be removed during this approach to improve visual 
acuity and color vision with a low rate of consecutive diplopia[98].
15. Transcaruncular
The transcaruncular approach allows for quick, safe access to the orbital apex for removal of 
the medial and inferior walls[43,89,99]. It allows for more medial wall exposure than the 
transcutaneous approach, but it avoids adverse structural or functional consequences 
associated with a cutaneous incision. (FIGURE 7)
Several studies demonstrate significant improvement in all parameters of optic nerve 
function after transcaruncular approach decompression, allowing for rapid steroid 
taper[42,43,100,101]. This technique allows for a graded approach to removing the 
ethmoidal air cells and the inferior wall to preserve as much of the maxillo-ethmoidal strut 
as desired, lowering the risk of new-onset postoperative diplopia[43,89]. A meta-analysis of 
techniques for DON surgical decompression described the transcaruncular approach as easy 
and safe access to the orbital apex[99].
16. Lateral Wall
Lateral wall decompression can be performed through an upper eyelid or lateral canthal 
incision, and involves removal of the deep lateral orbital wall, typically with a high-speed 
drill or ultrasonic aspirator [102–105]. Lateral wall-only decompression can be performed 
with or without fat removal, and results in a low rate of new-onset postoperative 
diplopia[106]. The lateral wall does not extend as far posteriorly as the medial wall, but 
aggressive deep bony decompression with or without fat removal seems to decompress the 
orbital apex effectively for treatment of DON[107]. (FIGURE 8)
17. Treatment Outcomes and Quality of Life
Without treatment, DON may result in permanent vision loss[25]. Fortunately, regimens 
consisting of iv-MP, ORT, and surgical decompression effectively improve visual outcome in 
the vast majority of cases with complete visual recovery in approximately 70% of cases 
[14,19]. Positive predictive factors include younger age, shorter duration of neuropathy, and 
higher initial CAS, likely indicating earlier disease course[19]. Though quality of life (QoL) 
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comprises an essential aspect of treatment outcome, it is far less commonly assessed and 
studied than clinical measures, especially for DON. Several studies have shown clinical 
measures to correlate poorly with QoL outcomes except in extreme cases, in which patients 
consistently report lower QoL scores[108].
18. Expert Commentary
Despite strong evidence to support the use of iv-GC as first-line treatment for moderate-
severe TED, recent survey results indicate that a large proportion of physicians still favor 
oral steroids, especially in the United States. This may be due to the association of iv-GC 
with severe, possibly fatal adverse events. However, studies consistently show that iv-GC are 
better tolerated, more effective, and associated with less morbidity compared to oral steroids. 
Creating safe treatment practices based on the available data entails awareness of safe dosing 
regimens, screening patients based on risk factors such as cardiovascular disease and DM, 
and close monitoring of liver enzymes and cardiac function throughout treatment. Also, 
while corticosteroids often decrease disease activity, they rarely result in proptosis reduction 
and surgical decompression may still be warranted.
While ORT may prevent DON in some patients, its indiscriminate use for DON would result 
in treatment of many patients who would not benefit from the therapy. Therefore, given the 
current data, we reserve ORT for patients with refractory DON who do not elect, or are poor 
candidates for, surgical decompression. While a variety of approaches adequately 
decompress the orbital apex, we typically employ a transcaruncular approach, or 
occasionally a transnasal endoscopic approach.
19. Five-year view
As our understanding of the environmental, genetic, and immune factors underlying Graves’ 
disease improves, future therapies will better target cellular and molecular mechanisms to 
prevent and treat DON. A promising animal model provides the opportunity to study the 
effects of novel drugs and treatments in vivo[109–111]. Pursuing studies that distinguish 
between the heterogeneous types of antibodies found in patients with DON will contribute 
greatly to understanding the pathophysiology of the disease, as well as provide more 
information on targets for treatment.
Reports of new treatment options for TED and DON are numerous, but data from controlled 
clinical trials are lacking. Well-designed clinical trials testing the efficacy of novel agents 
and surgical techniques will be essential in advancing and improving current treatment 
regimens and reducing disease mortality. This is especially true for treatments of DON, 
however, the rarity of this condition and the need for urgent treatment makes Level 1 data 
difficult to obtain. Efforts on the part of organizations such as EUGOGO and ITEDS will 
hopefully make possible organized multi-center randomized controlled trials, and provide 
valuable evidence-based data to enhance and refine techniques for managing both DON and 
TED.
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20. Key Issues
• Dysthyroid Optic Neuropathy (DON) can cause permanent vision loss and 
results from an orbital apex syndrome.
• In addition to thyroid dysfunction, male gender and older age are strong risk 
factors for development of DON while the role of tobacco status is less 
defined.
• Careful clinical evaluation for DON is critical and visual acuity, color vision, 
pupillary exam, contrast sensitivity, visual field testing, and visual evoked 
potential can aid in diagnosis and tracking progression.
• DON management involves obtaining a euthyroid state, protecting the ocular 
surface, and orbital decompression via medical or surgical means.
• Medical management of DON involves corticosteroids and some centers also 
employ orbital radiotherapy and/or immunosuppressive agents
• Surgical orbital decompression is often necessary for DON refractory to 
medical management.
• Prompt treatment in DON can result in stabilization and improvement in 
vision.
• Further studies, including randomized controlled clinical trials are necessary 
to better elucidate the role of novel agents and surgical techniques to better 
optimize DON management.
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Figure 1. 
Thyroid eye disease illustration. Various clinical manifestations found in moderate to severe 
thyroid eye disease are shown in this illustration
Original figure with Cleveland Clinic Foundation copyright 2015
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Figure 2. 
Orbital Fibroblast role in Thyroid Eye Disease
Original figure with Cleveland Clinic Foundation copyright 2016
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Figure 3. 
Clinical Evaluation of Optic Nerve Function in DON
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FIG. 4. 
A. Muscle Index measurement. B. Apical Crowding.
Original figure with Cleveland Clinic Foundation copyright 2016
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Figure 5. 
ORT isodose plan. Pretreatment evaluation involves isodose planning which can target x-
rays to specific anatomic locations. In this plan, the extraocular muscles are targeted along 
with orbital fat with attempt to minimize radiation to other important ocular structures. ORT, 
orbital radiation therapy.
Permission obtained for re-print from Chundury et al, Opthalmic Plastic and Reconstructive 
Surgery, 2015.
(Permission license present in previously uploaded files)
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Figure 6. 
Coronal CT scan post-orbital decompression for DON.
Original figure with Cleveland Clinic Foundation copyright 2016
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Figure 7. 
Transcaruncular approach to medial orbit
Original figure with Cleveland Clinic Foundation copyright 2016
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Figure 8. 
Lateral orbital decompression for DON
Original figure with Cleveland Clinic Foundation copyright 2016
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Table 1
Clinical Activity Score (CAS). Presence of each symptom/sign receives 1 point. A sum score greater than 3/7 
at first exam or greater than 4/10 in subsequent examinations defines active ophthalmopathy (altered after 
Mourits et al original description)
Initial Exam (max score of 7 points)
• Ocular or retrobulbar pain
• Pain with eye movement
• Eyelid erythema
• Eyelid swelling
• Conjunctival chemosis
• Conjunctival erythema
• Swelling/erythema of caruncle
Subsequent Exam, 1–3 months later (max score of 10 points, combining pa0ameters above and below)
• ≥2mm increase in proptosis
• Impaired ductions in any one direction >8 degrees
• ≥1 line decrease in Snellen visual acuity chart
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Table 2
VISA Inflammatory Score. Presence of each sign/symptom receives 1–2 points (max score of 10). Patients 
with sum scores <4/10 are managed conservatively while patients with scores >5/10 or with evidence of 
inflammatory progression are more aggressively treated (altered after Dolman and Rootman original 
description).
• Swelling of caruncle (1 point)
• Conjunctival chemosis that lies behind the grey line (1 point) OR extends anterior to grey line of eyelid (2 points)
• Conjunctival erythema (1 point)
• Eyelid erythema (1 point)
• Eyelid swelling without redundant tissues (1 point) OR swelling that causes bulging in the palpebral skin, including lower lid 
festoon (2 points)
• Retrobulbar pain at rest (1 point)
• Retrobulbar pain with eye movement (1 point)
• Diurnal variation (1 point)
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